PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...

Amyotrophic lateral sclerosis (ALS) received widespread attention in the summer of 2014 thanks to the Ice Bucket Challenge. Millions of people participated, drenching themselves in ice-cold water to ...

Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher Jeffrey Agar and a team of scientists came up with a technique that improves ...

Digging deep into the molecular mechanisms behind ALS, researchers at the Les Turner ALS Center at Northwestern Medicine have ...

Amyotrophic Lateral Sclerosis, or ALS, received widespread awareness in the summer of 2014 thanks to an Ice Bucket Challenge. Millions of people participated in the challenge, drenching themselves in ...

Why are so many amyotrophic lateral sclerosis (ALS) drug trials are failing? And what makes a new candidate drug called COYA 302, an investigational therapy for ALS, different? COYA 302 is a ...

Acting US Food and Drug Administration (FDA) Commissioner Ned Sharpless on Thursday announced that the agency would finalize guidance on developing treatments for amyotrophic lateral sclerosis (ALS) ...

Scientists have learned more about the effects of an experimental amyotrophic lateral sclerosis (ALS) drug candidate that failed its promise. This study has shown that the drug was able to enter the ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...